Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy

被引：39

作者：

Nakamura, Keiichiro ^{[1
]}

Nishida, Takeshi ^{[1
]}

Haruma, Tomoko ^{[1
]}

Haraga, Junko ^{[1
]}

Omichi, Chiaki ^{[1
]}

Ogawa, Chikako ^{[1
]}

Kusumoto, Tomoyuki ^{[1
]}

Seki, Noriko ^{[1
]}

Masuyama, Hisashi ^{[1
]}

Hiramatsu, Yuji ^{[1
]}

机构：

[1] Okayama Univ, Dept Obstet & Gynecol, Grad Sch Med Dent & Pharmaceut Sci, 2-5-1 Shikata Cho, Okayama, Okayama 7008558, Japan

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2015年 / 3卷 / 05期

关键词：

recurrent cervical cancer; platelet to lymphocyte ratio; prognosis predictor;

D O I：

10.3892/mco.2015.595

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of the present study was to identify the correlations between inflammation markers such as neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and C-reactive protein (CRP) and the prognosis in patients with recurrent cervical cancer. The associations among NLR, PLR and CRP and clinical characteristics and prognosis were examined in 32 patients receiving chemotherapy with recurrent cervical cancer following concurrent chemoradiation therapy (CCRT). The patient median survival time was 198 days (range, 42-1,022 days). Pretreatment NLR and PLR were significantly correlated with the recurrence of cervical cancer following CCRT (R=-0.538, P=0.002; and R=-0.542, P=0.001, respectively). Pretreatment PLR >322.0 was significantly associated with a poor prognosis for recurrent cervical cancer following CCRT by univariate and multivariate analyses (P=0.015 and P=0.029). These findings indicate that pretreatment PLR is an important predictor of prognosis in patients with recurrent cervical cancer following CCRT.

引用

页码：1001 / 1006

页数：6

共 39 条

[1]

Aliustaoglu M, 2010, HEPATO-GASTROENTEROL, V57, P640

[2]

ARSENEAU J, 1986, INVEST NEW DRUG, V4, P187

[3] TYPE-BETA TRANSFORMING GROWTH-FACTOR IN HUMAN-PLATELETS - RELEASE DURING PLATELET DEGRANULATION AND ACTION ON VASCULAR SMOOTH-MUSCLE CELLS [J].